{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:47:56Z","timestamp":1787064476799,"version":"build-2736575974"},"reference-count":36,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To provide a clinical overview of the antipsychotic lurasidone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>Articles were identified by searching the MEDLINE, PubMed, Cochrane Library, and EBSCO databases (through February 2012) using the key word lurasidone. The manufacturer provided information on unpublished Phase 2 and 3 trials. The Clinicaltrials.gov database was reviewed for the status of ongoing and upcoming trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION AND DATA EXTRACTION:<\/jats:title>\n                    <jats:p>All clinical trials lasting longer than 3 weeks and published in the English language were selected for review. Additional documentation, including the product dossier, package insert, and poster presentations supplied by the publisher, was also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>\n                      Lurasidone hydrochloride is an atypical antipsychotic that is approved for the treatment of schizophrenia. It is under investigation for treatment of bipolar I disorder. It should be administered with food, is pregnancy category B, is contraindicated for coadministration with strong CYP3A4 inducers and inhibitors, and requires dose adjustments with certain medications and in renal and hepatic impairment. Like other atypical antipsychotics, lurasidone possesses dopamine D\n                      <jats:sub>2<\/jats:sub>\n                      and serotonin 5-HT\n                      <jats:sub>2A<\/jats:sub>\n                      antagonism but exhibits little affinity for histamine H\n                      <jats:sub>1<\/jats:sub>\n                      , \u03b1\n                      <jats:sub>1<\/jats:sub>\n                      -adrenergic, or cholinergic M1 receptors. Additionally, it is a potent 5-HT\n                      <jats:sub>7<\/jats:sub>\n                      antagonist, which may impact depression and cognition. Phase 3 trial results revealed that 40-80 mg administered once daily resulted in statistically significant improvements in schizophrenia symptomatology compared with placebo. Lurasidone's rate of metabolic adverse events is low relative to other atypical antipsychotics; however, this is offset by dose-dependent increases in somnolence, akathisia, and parkinsonism.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Lurasidone has shown efficacy when compared to placebo in acute schizophrenia. Full characterization of the adverse effect profile and cognitive and affective benefits requires publication of trials with longer durations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1m721","type":"journal-article","created":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T01:49:31Z","timestamp":1343180971000},"page":"1033-1046","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":21,"title":["Lurasidone: An Atypical Antipsychotic for Schizophrenia"],"prefix":"10.1177","volume":"46","author":[{"given":"Vineeta","family":"Risbood","sequence":"first","affiliation":[{"name":"Vineeta Risbood PharmD BCPP BCPS, Clinical Pharmacy Specialist, Department of Pharmacy, Kaiser Permanente of Ohio, Parma, OH. The opinions and assertions contained herein are the private views of the author and are not to be construed as reflecting the views of Ohio Permanente Medical Group or the Kaiser Foundation Health Plan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R","family":"Lee","sequence":"additional","affiliation":[{"name":"Jennifer R Lee PharmD BCPP, Mental Health Clinical Pharmacy Specialist, Department of Pharmacy, Veterans Affairs Eastern Colorado Health Care System, Denver"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Roche-Desilets","sequence":"additional","affiliation":[{"name":"Jennifer Roche-Desilets PharmD BCPP BCPS, Clinical Pharmacy Specialist, Department of Pharmacy, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A","family":"Fuller","sequence":"additional","affiliation":[{"name":"Matthew A Fuller PharmD BCPP BCPS FASHP, Clinical Pharmacy Specialist, Psychiatry, Department of Pharmacy, Louis Stokes Cleveland Veterans Affairs Medical Center; Associate Clinical Professor of Psychiatry, Clinical Instructor of Psychology, Department of Medicine, Psychiatry Service, Case Western Reserve University, Cleveland; Adjunct Associate Professor of Clinical Pharmacy, University of Toledo, Toledo, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2012,7,1]]},"reference":[{"key":"bibr1-aph.1M721","volume-title":"Package insert. Latuda (lurasidone HCL) tablets","year":"2012"},{"key":"bibr2-aph.1M721","unstructured":"Lurasidone: a 24-week extension study of patients with bipolar I depression. http:\/\/clinicaltrials.gov\/show\/NCT00868959 (accessed 2009 Nov 19)."},{"key":"bibr3-aph.1M721","unstructured":"Lurasidone: a 6-week study of patients with bipolar I depression (monotherapy). http:\/\/clinicaltrials.gov\/show\/NCT00868699 (accessed 2009 Nov 19)."},{"key":"bibr4-aph.1M721","unstructured":"Lurasidone: a 6 week study of patients with bipolar I depression (add-on). http:\/\/clinicaltrials.gov\/show\/NCT00868452 (accessed 2009 Nov 19)."},{"key":"bibr5-aph.1M721","unstructured":"Lurasidone HCI: a 6-week phase 3 study of patients with bipolar I depression (PREVAIL3). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01284517 (accessed 2011 Jun 2)."},{"key":"bibr6-aph.1M721","unstructured":"Sunovion. Bipolar maintenance study of lurasidone adjunctive to lithium or divalproex (PERSIST). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01358357?term=NCT01358357&rank=1 (accessed 2011 Jun 2)."},{"key":"bibr7-aph.1M721","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903286388"},{"key":"bibr8-aph.1M721","unstructured":"Sunovion. RI-AME study of [ISOTHIAZOLYL-3-14C]-LURASIDONE. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01082146 (accessed 2011 Jun 2)."},{"key":"bibr9-aph.1M721","volume-title":"Product information. Latuda (lurasidone HCl) tablets","year":"2010"},{"key":"bibr10-aph.1M721","first-page":"327","volume-title":"Stahl's essential psychopharmacology","author":"Stahl S","year":"2008","edition":"3"},{"key":"bibr11-aph.1M721","doi-asserted-by":"publisher","DOI":"10.2174\/138955707781662663"},{"key":"bibr12-aph.1M721","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0022-3565(25)38596-4","volume":"268","author":"Roth BL","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr13-aph.1M721","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-009-1521-8"},{"key":"bibr14-aph.1M721","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2004.04.026"},{"key":"bibr15-aph.1M721","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2005.04.014"},{"key":"bibr16-aph.1M721","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2005.12.013"},{"key":"bibr17-aph.1M721","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2007.11.023"},{"key":"bibr18-aph.1M721","doi-asserted-by":"crossref","unstructured":"Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009;e1\u2013e8.","DOI":"10.4088\/JCP.08m04905"},{"key":"bibr19-aph.1M721","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10060907"},{"key":"bibr20-aph.1M721","unstructured":"Sunovion. A study to test the effectiveness and safety of a new medication in the treatment of schizophrenia. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00088634?term=NCT00088634&rank= 1(accessed 2011 Jun 2)."},{"key":"bibr21-aph.1M721","unstructured":"Sunovion. Lurasidone HCl: a phase 3 study of patients with acute schizophrenia. http:\/\/clinicaltrials.gov\/show\/NCT00549718 (accessed 2011 Jun 2)."},{"key":"bibr22-aph.1M721","unstructured":"Sunovion. Lurasidone HCl: a phase 3 study of patients with acute schizophrenia. http:\/\/clinicaltrials.gov\/show\/NCT00615433 (accessed 2011 Jun 2)."},{"key":"bibr23-aph.1M721","unstructured":"Sunovion. A comparison of study drug with placebo and haloperidol in patients with schizophrenia. http:\/\/clinicaltrials.gov\/show\/NCT00044044 (accessed 2009 Nov 19)."},{"key":"bibr24-aph.1M721","unstructured":"Sunovion. Lurasidone HCl: a 6-week phase 3 study of patients with acute schizophrenia. http:\/\/clinicaltrials.gov\/show\/NCT00790192 (accessed 2009 Nov 19)."},{"key":"bibr25-aph.1M721","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.01.004"},{"key":"bibr26-aph.1M721","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"bibr27-aph.1M721","unstructured":"Cucchiaro J, Pikalov A, Ogasa M, et al. Safety of lurasidone: pooled analysis of five placebo-controlled trials in patients with schizophrenia (poster). Presented at US Psychiatric and Mental Health Congress, November 18-21, 2010, Orlando, FL."},{"key":"bibr28-aph.1M721","unstructured":"Sunovion. Safety and tolerability study of drug to treat schizophrenia. http:\/\/clinicaltrials.gov\/show\/NCT00044005 (accessed 2009 Nov 19)."},{"key":"bibr29-aph.1M721","unstructured":"Sunovion. A study to test the safety and tolerability of a new medication in the treatment of schizophrenia. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00088621?term=NCT00088621&rank=1 (accessed 2011 Jun 2)."},{"key":"bibr30-aph.1M721","unstructured":"Sunovion. Lurasidone HCl: a long term safety phase 3 study of patients with clinically stable schizophrenia. http:\/\/clinicaltrials.gov\/show\/NCT00641745 (accessed 2009 Nov 19)."},{"key":"bibr31-aph.1M721","unstructured":"Dainippon Sumitomo Pharma. Study of lurasidone HCl in patients with chronic schizophrenia. http:\/\/clinicaltrials.gov\/show\/NCT00711269 (accessed 2009 Nov 19)."},{"key":"bibr32-aph.1M721","unstructured":"Sunovion. Lurasidone HCl: a long term phase 3 study of patients with chronic schizophrenia. http:\/\/clinicaltrials.gov\/show\/NCT00789698 (accessed 2009 Nov 19)."},{"key":"bibr33-aph.1M721","unstructured":"Sunovion. A study evaluating lurasidone for the treatment of schizophrenia or schizoaffective disorder in subjects switched from other antipsychotic agents (SWITCHCore). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01143077?term=NCT01143077&rank=1 (accessed 2011 Jun 2)."},{"key":"bibr34-aph.1M721","unstructured":"Sunovion. A study of subjects switched to lurasidone for the treatment of schizophrenia or schizoaffective disorder (Switch Ext). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01143090?term=NCT01143090&rank=1 (accessed 2011 Jun 2)."},{"key":"bibr35-aph.1M721","unstructured":"Sunovion. Clinical and biomarker assessment of efficacy of cognitive remediation in patients with schizophrenia stabilized on lurasidone. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01173874?term=NCT01173874&rank=1 (accessed 2011 Jun 2)."},{"key":"bibr36-aph.1M721","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02587.x"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1M721","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1M721","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1M721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:11:58Z","timestamp":1777374718000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1M721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":36,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1345\/aph.1M721"],"URL":"https:\/\/doi.org\/10.1345\/aph.1m721","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}